Molecular biomarkers such as isocitrate dehydrogenase 1 (IDH1) and O6-methylguanine-DNA methyltransferase (MGMT) play an important role in evaluating the prognosis of glioma patients (2, 3). This evidence concerns the gene MGMT and central nervous system cancer.